ProQR Announces Proposed Underwritten Public Offering of Ordinary Shares
October 15 2019 - 4:13PM
ProQR Therapeutics N.V. (Nasdaq:PRQR), a biopharmaceutical
company dedicated to changing lives through the creation of
transformative RNA medicines for severe genetic rare diseases,
today announced that it intends to offer and sell $50,000,000 of
its ordinary shares in an underwritten public offering. All of the
shares are being offered by ProQR. In addition, ProQR expects to
grant the underwriters a 30-day option to purchase up to an
additional $7,500,000 of ordinary shares, on the same terms and
conditions. The offering is subject to market conditions and other
closing conditions, and there can be no assurance as to whether or
when the offering may be completed, or as to the actual terms of
the offering.
ProQR intends to use the net proceeds from the offering to fund
ongoing research and development activities and for working capital
and other general corporate purposes.
Citigroup and Evercore ISI are acting as joint bookrunners for
the offering.
A shelf registration statement relating to the offered ordinary
shares was filed with the Securities and Exchange
Commission (SEC) on November 7, 2019, which was declared
effective on November 19, 2019. A preliminary prospectus
supplement related to the offering has been filed with
the SEC and is available on the SEC's website, located
at www.sec.gov. Copies of the preliminary prospectus
supplement and the accompanying prospectus relating to the offering
may be obtained from Citigroup Global Markets Inc., c/o
Broadridge Financial Solutions, 1155 Long Island
Avenue, Edgewood, NY 11717, or by telephone at (800)
831-9146; or Evercore ISI, Attention: Equity Capital Markets, 55
East 52nd Street, 36th Floor, New York, NY 10055, or by telephone
at (888) 474-0200 or by email at ecm.prospectus@evercore.com.
This press release shall not constitute an offer to sell or a
solicitation of an offer to buy these securities nor shall there be
any sale of these securities in any state or jurisdiction in which
such offer, solicitation or sale would be unlawful prior to
registration or qualification under the securities laws of any such
state or jurisdiction.
About ProQR
ProQR Therapeutics is dedicated to changing lives through the
creation of transformative RNA medicines for the treatment of
severe genetic rare diseases such as Leber’s congenital amaurosis
10, Usher syndrome type 2 and autosomal dominant retinitis
pigmentosa. Based on our unique proprietary RNA repair platform
technologies we are growing our pipeline with patients and loved
ones in mind.*Since 2012*
Forward-Looking Statements
This press release contains forward-looking statements. All
statements other than statements of historical fact are
forward-looking statements, which are often indicated by terms such
as “anticipate,” “believe,” “could,” “estimate,” “expect,” “goal,”
“intend,” “look forward to”, “may,” “plan,” “potential,” “predict,”
“project,” “should,” “will,” “would” and similar expressions.
Forward-looking statements are based on management’s beliefs and
assumptions and on information available to management only as of
the date of this press release. These forward-looking statements
include, but are not limited to, statements about the proposed
offering of ProQR’s ordinary shares and the use of proceeds
therefrom. These forward-looking statements involve risks and
uncertainties, many of which are beyond ProQR’s control, including
risk and uncertainties related to market conditions and
satisfaction of customary closing conditions related to the
proposed offering. There can be no assurance that ProQR will be
able to complete the proposed offering on the anticipated terms, or
at all. Applicable risks also include those that are included in
ProQR’s preliminary prospectus supplement and accompanying
prospectus filed with the SEC for the proposed public offering,
including the documents incorporated by reference therein, which
include ProQR’s Annual Report on Form 20-F for the year ended
December 31, 2018, and any subsequent SEC filings. Given these
risks, uncertainties and other factors, you should not place undue
reliance on these forward-looking statements, and we assume no
obligation to update these forward-looking statements, even if new
information becomes available in the future, except as required by
law.
ProQR Therapeutics N.V.: Smital ShahChief
Financial OfficerT: +1 415 231 6431 ir@proqr.com
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Mar 2024 to Apr 2024
ProQR Therapeutics NV (NASDAQ:PRQR)
Historical Stock Chart
From Apr 2023 to Apr 2024